# GlaxoSmithKline’s BLENREP approved by FDA for multiple myeloma

- Link: https://www.directorstalkinterviews.com/glaxosmithklines-blenrep-approved-by-fda-for-multiple-myeloma/412848950
- Published: 2020-08-06T07:22:15+01:00
- Author: Amilia Stone

**[GlaxoSmithKline](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)
pl**c ([LON:GSK](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l))
has announced the US Food and Drug Administration has approved BLENREP as a monotherapy
treatment for adult patients with relapsed or refractory multiple myeloma who have
received at least four prior therapies including an anti-CD38 monoclonal antibody,
a proteasome inhibitor and an immunomodulatory agent. This indication is approved
under accelerated approval based on response rate. Continued approval for this indication
may be contingent upon verification and description of clinical benefit in confirmatory
trials. BLENREP is the first anti-BCMA (B-cell maturation antigen) therapy approved
anywhere in the world.^([i])  

> **Dr Hal Barron, Chief Scientific Officer and President R&D, GSK, said**: “As 
> the second most common form of blood cancer in the US, multiple myeloma is an 
> incurable and devastating disease. BLENREP is the first approved anti-BCMA therapy
> and has the potential to transform the treatment of patients with relapsed or 
> refractory myeloma who have limited treatment options today.”

BLENREP is GSK’s fifth major medicine approval in 2020 across areas of significant
unmet medical need such as cancer, HIV and chronic kidney disease. This approval
marks the second FDA approval for GSK’s oncology portfolio in four months.

BLENREP employs a multi-faceted mechanism of action and is directed toward BCMA,
a cell-surface protein that plays an important role in the survival of plasma cells
and is expressed on multiple myeloma cells.^([ii]) The approval of BLENREP was based
on six-month primary results from the pivotal DREAMM-2 study, which enrolled patients
with relapsed or refractory multiple myeloma who had actively progressing disease
that had worsened despite current standard of care.  

> **Dr Sagar Lonial, MD, Chief Medical Officer, Winship Cancer Institute of Emory
> University in Atlanta, Georgia, Chair of Emory Department of Hematology and Medical
> Oncology and Principal Investigator for DREAMM-2, said: **“While treatable, refractory
> multiple myeloma is a significant clinical challenge with poor outcomes for patients
> whose disease has become resistant to the current standard of care. Due to the
> limited options currently available, these patients are often retreated with drugs
> from the same classes after they relapse, which is why the approval of BLENREP,
> the first anti-BCMA therapy, is significant for both patients and physicians alike.”

In the DREAMM-2 study, treatment with single-agent BLENREP 2.5 mg/kg every three
weeks demonstrated a clinically meaningful overall response rate (ORR) of 31% (97.5%
CI; 21-43) in patients who had received a median of seven prior lines of treatment(
n=97). The median duration of response (DoR) had not been reached at the six-month
analysis, but 73% of responders had a DoR equal to or greater than six months. The
most commonly reported adverse events (≥20%) were keratopathy, decreased visual 
acuity, nausea, blurred vision, pyrexia, infusion-related reactions, and fatigue.
Keratopathy is characterised as changes in the corneal epithelium as seen on eye
examination, which can manifest with or without symptoms.

Ocular adverse reactions occurred in 77% of the 218 patients in the pooled safety
population and included keratopathy (76%), changes in visual acuity (55%), blurred
vision (27%) and dry eye (19%). Corneal adverse events were monitored with eye exams
prior to each dose, allowing for dose reductions or interruptions as appropriate.
Patients also used preservative-free eye drops. Keratopathy leading to treatment
discontinuation affected 2.1% of patients in the 2.5 mg/kg cohort.^([iii])

BLENREP is available through participation in the BLENREP Risk Evaluation and Mitigation
Strategy (REMS), which was developed to ensure appropriate use of the medicine. 
The programme requires education for all physicians prescribing BLENREP and their
patients regarding the ocular risks associated with treatment as well as monitoring.
Additional information about the BLENREP REMS can be found at www.blenreprems.com
or 1-855-209-9188.

> **Paul Giusti, President and CEO of the Multiple Myeloma Research Foundation (
> MMRF), said:** “The approval of BLENREP is an important advancement for patients
> with relapsed or refractory multiple myeloma, as it brings a much-needed new treatment
> to patients who face limited options due to their progressing disease. We are 
> grateful for GSK’s continued commitment to myeloma patients and their families.”

In 2017, BLENREP was granted Breakthrough Therapy designation by the FDA, which 
is intended to facilitate the development of investigational medicines that have
shown clinical promise for conditions where there is significant unmet need.

**About multiple myeloma**

Multiple myeloma is the second most common blood cancer in the US and is generally
considered treatable, but not curable.^([iv]) In the US, more than 32,000 people
are estimated to be diagnosed with multiple myeloma this year and nearly 13,000 
people will die from the disease.^([v]) Research into new therapies is needed as
multiple myeloma commonly becomes refractory to available treatments.^([vi])

**About B-cell maturation antigen (BCMA)**
The normal function of BCMA is to promote
plasma cell survival by transduction of signals from two known ligands, BAFF (B-
cell activating factor) and APRIL (a proliferation-inducing ligand). This pathway
has been shown to be important for myeloma cell growth and survival. BCMA expression
is limited to B cells at later stages of development. BCMA is expressed at varying
levels in myeloma patients and BCMA membrane expression is universally detected 
in myeloma cell lines.^(ii)

**About ****BLENREP** **(belantamab mafodotin-blmf)**

BLENREP is an antibody drug conjugate comprising a humanised anti-B cell maturation
antigen (BCMA) monoclonal antibody conjugated to the cytotoxic agent auristatin 
F via non-cleavable linker. The drug linker technology is licensed from Seattle 
Genetics; monoclonal antibody is produced using POTELLIGENT Technology licensed 
from BioWa.

**IMPORTANT SAFETY INFORMATION FOR BLENREP**

**WARNING: OCULAR TOXICITY**

BLENREP caused changes in the corneal epithelium resulting in changes in vision,
including severe vision loss and corneal ulcer, and symptoms such as blurred vision
and dry eyes.

Conduct ophthalmic exams at baseline, prior to each dose, and promptly for worsening
symptoms. Withhold BLENREP until improvement and resume, or permanently discontinue,
based on severity.

Because of the risk of ocular toxicity, BLENREP is available only through a restricted
program under a Risk Evaluation and Mitigation Strategy (REMS) called the BLENREP
REMS.

**WARNINGS AND PRECAUTIONS**

**Ocular Toxicity: **Ocular adverse reactions occurred in 77% of the 218 patients
in the pooled safety population. Ocular adverse reactions included keratopathy (
76%), changes in visual acuity (55%), blurred vision (27%), and dry eye (19%). Among
patients with keratopathy (n = 165), 49% had ocular symptoms, 65% had clinically
relevant visual acuity changes (decline of 2 or more lines on Snellen Visual Acuity
in any eye), and 34% had both ocular symptoms and visual acuity changes.

Keratopathy: Keratopathy was reported as Grade 1 in 7% of patients, Grade 2 in 22%,
Grade 3 in 45%, and Grade 4 in 0.5% per the KVA scale. Cases of corneal ulcer (ulcerative
and infective keratitis) have been reported. Most keratopathy events developed within
the first 2 treatment cycles (cumulative incidence of 65% by Cycle 2). Of the patients
with Grade 2 to 4 keratopathy (n = 149), 39% recovered to Grade 1 or lower after
median follow-up of 6.2 months. Of the 61% who had ongoing keratopathy, 28% were
still on treatment, 9% were in follow-up, and in 24% the follow-up ended due to 
death, study withdrawal, or lost to follow-up. For patients in whom events resolved,
the median time to resolution was 2 months (range: 11 days to 8.3 months).

Visual Acuity Changes: A clinically significant decrease in visual acuity of worse
than 20/40 in the better-seeing eye was observed in 19% of the 218 patients and 
of 20/200 or worse in the better-seeing eye in 1.4%. Of the patients with decreased
visual acuity of worse than 20/40, 88% resolved and the median time to resolution
was 22 days (range: 7 days to 4.2 months). Of the patients with decreased visual
acuity of 20/200 or worse, all resolved and the median duration was 22 days (range:
15 to 22 days).

Monitoring and Patient Instruction: Conduct ophthalmic examinations (visual acuity
and slit lamp) at baseline, prior to each dose, and promptly for worsening symptoms.
Perform baseline examinations within 3 weeks prior to the first dose. Perform each
follow-up examination at least 1 week after the previous dose and within 2 weeks
prior to the next dose. Withhold BLENREP until improvement and resume at same or
reduced dose, or consider permanently discontinuing based on severity. Advise patients
to use preservative-free lubricant eye drops at least 4 times a day starting with
the first infusion and continuing until end of treatment. Avoid use of contact lenses
unless directed by an ophthalmologist. Changes in visual acuity may be associated
with difficulty for driving and reading. Advise patients to use caution when driving
or operating machinery. BLENREP is only available through a restricted program under
a REMS.

BLENREP REMS: BLENREP is available only through a restricted program under a REMS
called the BLENREP REMS because of the risks of ocular toxicity. Notable requirements
of the BLENREP REMS include the following:

·      Prescribers must be certified with the program by enrolling and completing
training in the BLENREP REMS.

·      Prescribers must counsel patients receiving BLENREP about the risk of ocular
toxicity and the need for ophthalmic examinations prior to each dose.

·      Patients must be enrolled in the BLENREP REMS and comply with monitoring.

·      Healthcare facilities must be certified with the program and verify that 
patients are authorized to receive BLENREP.

·      Wholesalers and distributers must only distribute BLENREP to certified healthcare
facilities.

Further information is available at www.BLENREPREMS.com and 1-855-209-9188.

**Thrombocytopenia: **Thrombocytopenia occurred in 69% of 218 patients in the pooled
safety population, including Grade 2 in 13%, Grade 3 in 10%, and Grade 4 in 17%.
The median time to onset of the first thrombocytopenic event was 26.5 days. Thrombocytopenia
resulted in dose reduction, dose interruption, or discontinuation in 9%, 2.8%, and
0.5% of patients, respectively. Grade 3 to 4 bleeding events occurred in 6% of patients,
including Grade 4 in 1 patient. Fatal adverse reactions included cerebral hemorrhage
in 2 patients. Perform complete blood cell counts at baseline and during treatment
as clinically indicated. Consider withholding and/or reducing the dose based on 
severity.

**Infusion-Related Reactions: **Infusion-related reactions occurred in 18% of 218
patients in the pooled safety population, including Grade 3 in 1.8%_._ Monitor patients
for infusion-related reactions. For Grade 2 or 3 reactions, interrupt the infusion
and provide supportive treatment. Once symptoms resolve, resume at a lower infusion
rate. Administer premedication for all subsequent infusions. Discontinue BLENREP
for life-threatening infusion-related reactions and provide appropriate emergency
care.

**Embryo-Fetal Toxicity: **Based on its mechanism of action, BLENREP can cause fetal
harm when administered to a pregnant woman because it contains a genotoxic compound(
the microtubule inhibitor, monomethyl auristatin F [MMAF]) and it targets actively
dividing cells. Advise pregnant women of the potential risk to a fetus. Advise females
of reproductive potential to use effective contraception during treatment with BLENREP
and for 4 months after the last dose. Advise males with female partners of reproductive
potential to use effective contraception during treatment with BLENREP and for 6
months after the last dose.

**ADVERSE REACTIONS**

The pooled safety population described in _Warnings and Precautions_ reflects exposure
to BLENREP at a dosage of 2.5 mg/kg or 3.4 mg/kg (1.4 times the recommended dose)
administered intravenously once every 3 weeks in 218 patients in DREAMM-2. Of these
patients, 194 received a liquid formulation (not the approved dosage form) rather
than the lyophilized powder. Among the 218 patients, 24% were exposed for 6 months
or longer.

The safety of BLENREP as a single agent was evaluated in DREAMM-2. Patients received
BLENREP at the recommended dosage of 2.5 mg/kg administered intravenously once every
3 weeks (n = 95). Among these patients, 22% were exposed for 6 months or longer.

Serious adverse reactions occurred in 40% of patients who received BLENREP. Serious
adverse reactions in >3% of patients included pneumonia (7%), pyrexia (6%), renal
impairment (4.2%), sepsis (4.2%), hypercalcemia (4.2%), and infusion-related reactions(
3.2%). Fatal adverse reactions occurred in 3.2% of patients, including sepsis (1%),
cardiac arrest (1%), and lung infection (1%).

Permanent discontinuation due to an adverse reaction occurred in 8% of patients 
who received BLENREP; keratopathy (2.1%) was the most frequent adverse reaction 
resulting in permanent discontinuation.

Dosage interruptions due to an adverse reaction occurred in 54% of patients who 
received BLENREP. Adverse reactions which required a dosage interruption in >3% 
of patients included keratopathy (47%), blurred vision (5%), dry eye (3.2%), and
pneumonia (3.2%).

Dose reductions due to an adverse reaction occurred in 29% of patients. Adverse 
reactions which required a dose reduction in >3% of patients included keratopathy(
23%) and thrombocytopenia (5%).

The most common adverse reactions (≥20%) were keratopathy (71%), decreased visual
acuity (53%), nausea (24%), blurred vision (22%), pyrexia (22%), infusion-related
reactions (21%), and fatigue (20%). The most common Grade 3 or 4 (≥5%) laboratory
abnormalities were lymphocytes decreased (22%), platelets decreased (21%), hemoglobin
decreased (18%), neutrophils decreased (9%), creatinine increased (5%), and gamma-
glutamyl transferase increased (5%).

**USE IN SPECIFIC POPULATIONS**

**Lactation: **There is no data on the presence of belantamab mafodotin-blmf in 
human milk or the effects on the breastfed child or milk production. Because of 
the potential for serious adverse reactions in the breastfed child, advise women
not to breastfeed during treatment with BLENREP and for 3 months after the last 
dose.

**Females and Males of Reproductive Potential: **BLENREP can cause fetal harm when
administered to pregnant women. There are no available data on the use of BLENREP
in pregnant women to evaluate for drug-associated risk. No animal reproduction studies
were conducted with BLENREP.

Pregnancy Testing: Pregnancy testing is recommended for females of reproductive 
potential prior to initiating BLENREP.

Infertility: Based on findings in animal studies, BLENREP may impair fertility in
females and males. The effects were not reversible in male rats but were reversible
in female rats.

**Geriatric Use: **Of the 218 patients who received BLENREP in DREAMM-2, 43% were
aged 65 to less than 75 years and 17% were aged 75 years and older. Keratopathy 
occurred in 80% of patients aged less than 65 years and 73% of patients aged 65 
years and older. Among the patients who received BLENREP at the 2.5-mg/kg dose in
DREAMM-2 (n = 95), keratopathy occurred in 67% of patients aged less than 65 years
and 73% of patients aged 65 years and older.

**Renal Impairment: **No dose adjustment is recommended for patients with mild or
moderate renal impairment (estimated glomerular filtration rate [eGFR] 30 to 89 
mL/min/1.73m^(2) as estimated by the Modification of Diet in Renal Disease [MDRD]
equation). The recommended dosage has not been established in patients with severe
renal impairment (eGFR 15 to 29 mL/min/1.73 m^(2)) or end-stage renal disease (ESRD)
with eGFR <15 mL/min/1.73 m^(2) not on dialysis or requiring dialysis.

**Hepatic Impairment: **No dose adjustment is recommended for patients with mild
hepatic impairment (total bilirubin ≤upper limit of normal [ULN] and aspartate aminotransferase(
AST) >ULN or total bilirubin 1 to ≤1.5 × ULN and any AST). The recommended dosage
of BLENREP has not been established in patients with moderate or severe hepatic 
impairment (total bilirubin >1.5 × ULN and any AST)_._

**INDICATION**

BLENREP is indicated for the treatment of adults with relapsed or refractory multiple
myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal
antibody, a proteasome inhibitor, and an immunomodulatory agent.

This indication is approved under accelerated approval based on response rate. Continued
approval for this indication may be contingent upon verification and description
of clinical benefit in a confirmatory trial(s).

**Editor’s Note: **In addition to the FDA’s approval of BLENREP, GlaxoSmithKline
has received four major medicine approvals to date in 2020 for CABENUVA (cabotegravir
and rilpivirine) in Canada, DUVROQ (daprodustat) in Japan and ZEJULA (niraparib)
and RUKOBIA (fostemsavir) in the US.

Share on:
